Joshua Ofman, MD, MBA, serves as President of GRAIL, Inc., a pioneering healthcare company revolutionizing early cancer detection through innovative multi-cancer early detection (MCED) tests like Galleri. With over two decades of leadership in biotechnology, pharmaceuticals, and health policy, Ofman brings a unique physician-executive perspective to his role. He holds an MD from the David Geffen School of Medicine at UCLA and an MBA from the UCLA Anderson School of Management. Early in his career, he served as a Senior Advisor in the Office of the Administrator at the Centers for Medicare & Medicaid Services (CMS), shaping national health policy, and later held key roles at Bristol-Myers Squibb, focusing on outcomes research and market access. Ofman's commercial expertise flourished at Allergan, where he rose to Senior Vice President and Head of U.S. Specialty Care, driving growth in immunology, neuroscience, and ophthalmology portfolios. He then joined Amgen as Executive Vice President and Chief Commercial Officer, overseeing a $20 billion U.S. commercial organization, launching blockbuster therapies, and advancing patient access initiatives across oncology, cardiovascular, and rare diseases. His strategic leadership has consistently delivered double-digit revenue growth and market leadership, earning recognition for innovative go-to-market strategies and stakeholder engagement. At GRAIL, Ofman leads the company's commercialization efforts, scaling the adoption of transformative technologies to detect cancers earlier when they are more treatable. Under his guidance, GRAIL has expanded its commercial infrastructure, forged key partnerships, and advanced clinical evidence generation, positioning the company to fulfill its mission of changing the trajectory of cancer mortality. Ofman's vision emphasizes equitable access and data-driven innovation, solidifying GRAIL's role at the forefront of precision oncology.